Sandbox vidit5: Difference between revisions

Jump to navigation Jump to search
Line 54: Line 54:


{{familytree/start}}
{{familytree/start}}
{{familytree | | | | | | | | | A01 | | | | | | | | | | |A01=<div style="float: left; text-align: left "> ''' Characterize the symptoms:''' <br> ❑ Fever <br> ❑ Hypothermia <br> ❑ Altered mental status <br> ❑ Mottling <br> ❑ Ileus <br> ❑ Oliguria </div>}}
{{familytree | | | | | | | | | A01 | | | | | | | | | | |A01=<div style="float: left; text-align: left "> ''' Characterize the symptoms:''' <br> ❑ Fever <br> ❑ [[Hypothermia]] <br> ❑ Altered mental status <br> ❑ [[Mottling]] <br> ❑ [[Ileus]] <br> ❑ [[Oliguria]] </div>}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | B01 | | | | | | | | | | |B01=<div style="float: left; text-align: left "> '''Examine the patient:''' <br> ❑ Tachycardia <br> ❑ Tachypnea <br> ❑ Edema <br> ❑ Hyperglycemia <br> ❑ Hypotension after an initial 30 ml/Kg bolus <br> ❑ Decreased capillary refill </div> }}
{{familytree | | | | | | | | | B01 | | | | | | | | | | |B01=<div style="float: left; text-align: left "> '''Examine the patient:''' <br> ❑ Tachycardia <br> ❑ Tachypnea <br> ❑ Edema <br> ❑ Hyperglycemia <br> ❑ Hypotension after an initial 30 ml/Kg bolus <br> ❑ Decreased capillary refill </div> }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | C01 | | | | | | | | | | |C01=<div style="float: left; text-align: left "> '''Order labs:''' <br> ❑ Random blood sugar (RBS) <br> ❑ Complete blood count (CBC) <br> ❑ Plasma C reactive protein (CRP) <br> ❑ Plasma procalcitonin <br> ❑ Pulse oximetry <br> ❑ Urinalysis/Renal function tests <br> ❑ PT/INR <br> ❑ Liver function tests <br> ❑ Serum lactate <br> ❑ Central venous pressure (CVP) </div> }}
{{familytree | | | | | | | | | C01 | | | | | | | | | | |C01=<div style="float: left; text-align: left "> '''Order labs:''' <br> ❑ Random blood sugar (RBS) <br> ❑ Complete blood count (CBC) <br> ❑ [[C-reactive protein|Plasma C reactive protein (CRP)]] <br> ❑ [[Procalcitonin|Plasma procalcitonin]] <br> ❑ Pulse oximetry <br> ❑ Urinalysis/Renal function tests <br> ❑ PT/INR <br> ❑ Liver function tests <br> ❑ Serum lactate <br> ❑ Central venous pressure (CVP) </div> }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | D01 | | | | | | | | | | |D01=<div style="float: left; text-align: left "> '''Consider alternative diagnosis:''' <br> ❑ Infections <br> ❑ Acute pancreatitis <br> ❑ Diabetic ketoacidosis <br> Lower gastrointestinal bleeding <br> Myocardial infarction </div>}}
{{familytree | | | | | | | | | D01 | | | | | | | | | | |D01=<div style="float: left; text-align: left "> '''Consider alternative diagnosis:''' <br> ❑ Infections <br> ❑ [[Acute pancreatitis]] <br> ❑ [[Diabetic ketoacidosis]] <br> [[Lower gastrointestinal bleeding]] <br> [[Myocardial infarction]] </div>}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | E01 | | | | | | | | | | |E01=<div style="float: left; text-align: left "> '''Initial resuscitation: Goals to achieve in first 6 hours''' <br> ❑ CVP 8-12 mm Hg <br> ❑ Mean arterial pressure (MAP) ≥ 65 mm Hg <br> ❑ Urine output ≥ 0/5 mL/Kg/hr <br> ❑ Central venous O<sub>2</sub> sat. 70% <br> ❑ If lactate levels elevated, target is normalization </div>}}
{{familytree | | | | | | | | | E01 | | | | | | | | | | |E01=<div style="float: left; text-align: left "> '''Initial resuscitation: Goals to achieve in first 6 hours''' <br> ❑ Central venous pressure (CVP) 8-12 mm Hg <br> ❑ Mean arterial pressure (MAP) ≥ 65 mm Hg <br> ❑ Urine output ≥ 0/5 mL/Kg/hr <br> ❑ Central venous O<sub>2</sub> sat. 70% <br> ❑ If lactate levels elevated, target is normalization </div>}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | F01 | | | | | | | | | | |F01=<div style="float: left; text-align: left "> '''Diagnosis:''' <br> ❑ Perform 2 sets of blood cultures (aerobic and anaerobic) atleast, before starting antibiotics <br>
{{familytree | | | | | | | | | F01 | | | | | | | | | | |F01=<div style="float: left; text-align: left "> '''Diagnosis:''' <br> ❑ Perform 2 sets of blood cultures (aerobic and anaerobic) atleast, before starting antibiotics <br>
:# Drawn percutaneously <br>
:# Drawn percutaneously <br>
:# Drawn through each vascular access device present for > 48 hours <br>
:# Drawn through each vascular access device present for > 48 hours <br>
❑ Perform 1,3 beta-D_glucan assay, mannan, anti-mannan antibody assay if available <br> ❑ Perform imaging studies as appropriate to locate a source </div> }}
❑ Perform 1,3 beta-D-glucan assay, mannan, anti-mannan antibody assay if available <br> ❑ Perform imaging studies as appropriate to locate a source </div> }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | | }}
{{familytree | | | | | | | | | G01 | | | | | | | | | | |G01=<div style="float: left; text-align: left "> '''Antimicrobial therapy:''' <br> ❑ Initiate within 1st hour of diagnosis <br> Reassess regimen daily <br> ❑ Use low procalitonin levels for prognosis <br> ❑ Usual duration of therapy 10 days <br> ❑ Longer in neutropenics, slow responders, undrainable foci, immunologically compromised </div>}}
{{familytree | | | | | | | | | G01 | | | | | | | | | | |G01=<div style="float: left; text-align: left "> '''Antimicrobial therapy:''' <br> ❑ Initiate within 1st hour of diagnosis <br> Reassess regimen daily <br> ❑ Use low procalitonin levels for prognosis <br> ❑ Usual duration of therapy 10 days <br> ❑ Longer in neutropenics, slow responders, undrainable foci, immunologically compromised </div>}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | H01 | | | | | | | | | | |H01=Choice of antibiotics }}
{{familytree | | | | | | | | | H01 | | | | | | | | | | |H01=Choice of antibiotics }}
{{familytree | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | |,|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|.| | | }}
{{familytree | |,|-|-|-|v|-|-|-|+|-|-|-|v|-|-|-|.| | | }}
{{familytree | I01 | | I02 | | I03 | | I04 | | I05 | | |I01='''Unknown organism''' <br> ❑ Empiric therapy with broad spectrum antbiotic with good tissue penetrance |I02= '''Neutropenic pt with severe sepsis (goal is to cover Acinetobacter & Pseudomonas spp)''' <br> ❑ Use combination empirical therapy |I03='''Severe infections + resp failure + septic shock''' <br> ❑ Extended spectrum beta lactam and aminoglycoside/fluoroquinolone |I04= '''Streptococcus pneumoniae'' <br> ❑ Beta lactam + macrolide |I05='''Culture specific organism''' <br> ❑ Shift to appropriate anti-bacterial, antiviral or antifungal  }}
{{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | I01 | | I02 | | I03 | | I04 | | I05 | | |I01='''Unknown organism''' <br> ❑ Empiric therapy with broad spectrum antbiotic with good tissue penetrance |I02= '''[[Neutropenic]] pt with severe sepsis (goal is to cover [[Acinetobacter]] & [[Pseudomonas]] spp)''' <br> ❑ Use combination empirical therapy |I03='''Severe infections + resp failure + septic shock''' <br> ❑ Extended spectrum [[Beta-lactam antibiotic|beta lactam]] and [[aminoglycoside]]/[[fluoroquinolone]] |I04= '''[[Streptococcus pneumoniae]]''' <br> ❑ [[Beta-lactam antibiotic|beta lactam]] + [[macrolide]] |I05='''Culture specific organism''' <br> ❑ Shift to appropriate anti-bacterial, antiviral or antifungal  }}
 
{{familytree | |!| | | |!| | | |!| | | |!| | | |!| | | }}
{{familytree | |`|-|-|-|^|-|-|-|+|-|-|-|^|-|-|-|'| | | }}
{{familytree | |`|-|-|-|^|-|-|-|+|-|-|-|^|-|-|-|'| | | }}
{{familytree | | | | | | | | | J01 | | | | | | | | | |J01=<div style="float: left; text-align: left "> '''Remove source/foci of infection:''' <br> ❑ Use minimally invasive process <br> ❑ Source removal best done in first 12 hours <br> ❑ Remove intravascular access devices if they are a possible source
{{familytree | | | | | | | | | J01 | | | | | | | | | |J01=<div style="float: left; text-align: left "> '''Remove source/foci of infection:''' <br> ❑ Use minimally invasive process <br> ❑ Source removal best done in first 12 hours <br> ❑ Remove intravascular access devices if they are a possible source
----
----
❑ Oral chlorhexidine gluconate to reduce oral contamination as a risk factor for ventilator associated pneumonia </div> }}
❑ Oral [[chlorhexidine gluconate]] to reduce oral contamination as a risk factor for [[ventilator associated pneumonia]] </div> }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | K01 | | | | | | | | | |K01=<div style="float: left; text-align: left "> Hemodynamic support <br> '''Fluid therapy:''' <br> ❑ Administer crystalloids, use albumin when demand for fluids is too high <br> ❑ Use dynamic variables (change in pulse pressure, stroke volume) and static variables (arterial pressure,heart rate) to assess status
{{familytree | | | | | | | | | K01 | | | | | | | | | |K01=<div style="float: left; text-align: left "> Hemodynamic support <br> '''Fluid therapy:''' <br> ❑ Administer [[crystalloids]], use albumin when demand for fluids is too high <br> ❑ Use dynamic variables (change in pulse pressure, stroke volume) and static variables (arterial pressure,heart rate) to assess status
----
----
'''Vasopressors (to achieve target MAP 65 mm Hg):''' <br> ❑ Place arterial line as soon as feasible <br> ❑ Administer norepinephrine as 1st choice drug <br> ❑ Use epinephrine - when additional agent needed <br> ❑ Use vasopressin 0.03 units/minute to raise MAP or decrease norepinephrine usage <br> ❑ Selective dopamine (absolute or relative bradycardia) and phenylephrine usage
'''[[Vasopressors]] (to achieve target MAP 65 mm Hg):''' <br> ❑ Place [[arterial line]] as soon as feasible <br> ❑ Administer [[norepinephrine]] as 1st choice drug <br> ❑ Use [[epinephrine]] - when additional agent needed <br> ❑ Use [[vasopressin]] 0.03 units/minute to raise MAP or decrease norepinephrine usage <br> ❑ Selective [[dopamine]] (absolute or relative bradycardia) and [[phenylephrine]] usage
----
----
'''Inotropic therapy:''' <br> ❑ Trial of dobutamine infusion 20 μg/Kg if cardiac output low with elevated cardiac filling pressure </div> }}
'''Inotropic therapy:''' <br> ❑ Trial of [[dobutamine]] infusion 20 μg/Kg if cardiac output low with elevated cardiac filling pressure </div> }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | L01 | | | | | | | | | |L01=<div style="float: left; text-align: left "> '''Corticosteroids:''' <br> ❑ Use continuous flow IV hydrocortisone 200 mg/day if shock doesn’t improve with fluids & vasopressor <br> ❑ Taper when vasopressors no longer required </div> }}
{{familytree | | | | | | | | | L01 | | | | | | | | | |L01=<div style="float: left; text-align: left "> '''Corticosteroids:''' <br> ❑ Use continuous flow IV [[hydrocortisone]] 200 mg/day if shock doesn’t improve with fluids & vasopressor <br> ❑ Taper when vasopressors no longer required </div> }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | M01 | | | | | | | | | |M01=<div style="float: left; text-align: left "> '''Blood products:''' <br> ❑ Transfuse blood when hemoglobin < 7.0 g/dL <br> ❑ Transfuse platelets if < 10,000/mm<sup>3</sup> or < 20,000/mm<sup>3</sup> in those with high risk </div> }}
{{familytree | | | | | | | | | M01 | | | | | | | | | |M01=<div style="float: left; text-align: left "> '''Blood products:''' <br> ❑ Transfuse blood when hemoglobin < 7.0 g/dL <br> ❑ Transfuse platelets if < 10,000/mm<sup>3</sup> or < 20,000/mm<sup>3</sup> in those with high risk </div> }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | N01 | | | | | | | | | |N01=<div style="float: left; text-align: left "> '''Mechanical ventilation for sepsis induced ARDS':'' <br> ❑ Target tidal volume of 6 mL/Kg <br> ❑ Target plateau pressure ≤ 30 mm Hg <br> ❑ Use PEEP (positive end expiratory pressure) to avoid alveolar collapse <br> ❑ Raise patients bed to 30-45° <br> ❑ Attempt weaning when all foll. criteria are met: <br>
{{familytree | | | | | | | | | N01 | | | | | | | | | |N01=<div style="float: left; text-align: left "> '''Mechanical ventilation for sepsis induced ARDS':''' <br> ❑ Target tidal volume of 6 mL/Kg <br> ❑ Target plateau pressure ≤ 30 mm Hg <br> ❑ Use PEEP (positive end expiratory pressure) to avoid alveolar collapse <br> ❑ Raise patients bed to 30-45° <br> ❑ Attempt weaning when all foll. criteria are met: <br>
:# ❑ Pt arousable
:# ❑ Pt arousable
:# ❑ Hemodynamics stable
:# ❑ Hemodynamics stable
Line 100: Line 98:
❑ Extubate when weaning successful </div>}}
❑ Extubate when weaning successful </div>}}
{{familytree | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | |!| | | | | | | | | | | }}
{{familytree | | | | | | | | | O01 | | | | | | | | | |O01=<div style="float: left; text-align: left "> Other supportive therapy <br> '''Sedation & neuromuscular blockade:''' <br> ❑ Use minimal sedation/neuromuscular blockade in mechanically ventilated patients
{{familytree | | | | | | | | | O01 | | | | | | | | | |O01=<div style="float: left; text-align: left "> Other supportive therapy <br> '''Sedation & neuromuscular blockade:''' <br> ❑ Use minimal sedation/[[Neuromuscular-blocking drugs|neuromuscular blockade]] in mechanically ventilated patients
----
----
'''Glucose control:''' <br> ❑ Blood glucose target value should be ≤ 180 mg/dL <br> ❑ Use insulin infusion and 1-2 hourly monitoring to achieve target
'''Glucose control:''' <br> ❑ Blood glucose target value should be ≤ 180 mg/dL <br> ❑ Use insulin infusion and 1-2 hourly monitoring to achieve target
----
----
'''Renal replaement therapy:''' <br> ❑ May be used for management of fluid balance in hemodynamically unstable patients <br> ❑ Use for septic patients with acute renal failure
'''Renal replaement therapy:''' <br> ❑ May be used for management of fluid balance in hemodynamically unstable patients <br> ❑ Use for septic patients with [[acute renal failure]]
----
----
'''DVT prophylaxis:''' <br> ❑ Do pharmacoprophylaxis with low molecular weight heparin (LMWH), if no contraindications present <br> ❑ Use pneumatic compression devices whenever possible
'''DVT prophylaxis:''' <br> ❑ Do pharmacoprophylaxis with [[low molecular weight heparin]] (LMWH), if no contraindications present <br> ❑ Use [[Intermittent pneumatic compression|pneumatic compression devices]] whenever possible
----
----
'''Stress ulcer prophylaxis''' <br> ❑ Consider prophylaxis if risk factors are present
'''Stress ulcer prophylaxis''' <br> ❑ Consider prophylaxis if risk factors are present
Line 116: Line 114:
{{familytree | | | | | | | | | | | | | | | | | | | | | }}
{{familytree | | | | | | | | | | | | | | | | | | | | | }}
{{familytree/end}}
{{familytree/end}}


==Do's==
==Do's==

Revision as of 16:02, 21 January 2014

Definition

Sepsis is a systemic, deleterious host response to infection, manifested as multi system organ dysfunction plus hypotension, that is not readily reversible with fluid resuscitation.

Diagnostic Criteria For Sepsis

(Documented/Suspected Infection Plus Inflammatory variables Plus One of The Organ Dysfunction)

General variables
  • Fever > 38.3°C
  • Hypothermia (core temperature < 36°C)
  • Heart rate > 90/min–1 or > 2 Standard deviation (SD) above the normal value for age
  • Tachypnea
  • Altered mental status
  • Edema
  • Positive fluid balance ( > 20 mL/kg over 24 hr)
  • Hyperglycemia (plasma glucose > 140 mg/dL or 7.7 mmol/L) in the absence of diabetes
Inflammatory variables
  • Leukocytosis (WBC count > 12,000 µL–1)
  • Leukopenia (WBC count < 4000 µL–1)
  • Immature WBCs forms are > 10% with normal count
  • Plasma C-reactive protein > 2 SD above the normal value
  • Plasma procalcitonin > 2 SD above the normal value
Hemodynamic variables
  • Arterial hypotension after 30 ml/kg fluid bolus (Systolic blood pressure (SBP) < 90 mm Hg, mean arterial pressure (MAP) < 70 mm Hg, or an SBP decrease > 40 mm Hg in adults or < 2 SD below normal for age)
Organ dysfunction variables
  • Arterial hypoxemia (Pao2/Fio2 < 300)
  • Acute oliguria (urine output < 0.5 mL/kg/hr for at least 2 hrs despite adequate fluid resuscitation)
  • Creatinine increase > 0.5 mg/dL or 44.2 µmol/L
  • Coagulation abnormalities (INR > 1.5 or aPTT > 60 Sec)
  • Ileus (absent bowel sounds)
  • Thrombocytopenia (platelet count < 100,000 µL–1)
  • Hyperbilirubinemia (plasma total bilirubin > 4 mg/dL or 70 µmol/L)
Tissue perfusion variables
  • Hyperlactatemia > 1 mmol/L
  • Decreased capillary refill or mottling

Diagnostic Criteria for Severe Sepsis (sepsis induced hypoperfusion or organ dysfunction)

Includes any one of the following caused due to the infection:

  • Sepsis-induced hypotension
  • Lactate above upper limits laboratory normal
  • Urine output < 0.5 mL/kg/hr for more than 2 hrs despite adequate fluid resuscitation
  • Acute lung injury with Pao2/Fio2 < 250 in the absence of pneumonia as infection source
  • Acute lung injury with Pao2/Fio2 < 200 in the presence of pneumonia as infection source
  • Creatinine > 2.0 mg/dL (176.8 μmol/L)
  • Bilirubin > 2 mg/dL (34.2 μmol/L)
  • Platelet count < 100,000 μL
  • Coagulopathy (international normalized ratio > 1.5)

Management

 
 
 
 
 
 
 
 
Characterize the symptoms:
❑ Fever
Hypothermia
❑ Altered mental status
Mottling
Ileus
Oliguria
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:
❑ Tachycardia
❑ Tachypnea
❑ Edema
❑ Hyperglycemia
❑ Hypotension after an initial 30 ml/Kg bolus
❑ Decreased capillary refill
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order labs:
❑ Random blood sugar (RBS)
❑ Complete blood count (CBC)
Plasma C reactive protein (CRP)
Plasma procalcitonin
❑ Pulse oximetry
❑ Urinalysis/Renal function tests
❑ PT/INR
❑ Liver function tests
❑ Serum lactate
❑ Central venous pressure (CVP)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Initial resuscitation: Goals to achieve in first 6 hours
❑ Central venous pressure (CVP) 8-12 mm Hg
❑ Mean arterial pressure (MAP) ≥ 65 mm Hg
❑ Urine output ≥ 0/5 mL/Kg/hr
❑ Central venous O2 sat. 70%
❑ If lactate levels elevated, target is normalization
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnosis:
❑ Perform 2 sets of blood cultures (aerobic and anaerobic) atleast, before starting antibiotics
  1. Drawn percutaneously
  2. Drawn through each vascular access device present for > 48 hours
❑ Perform 1,3 beta-D-glucan assay, mannan, anti-mannan antibody assay if available
❑ Perform imaging studies as appropriate to locate a source
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antimicrobial therapy:
❑ Initiate within 1st hour of diagnosis
Reassess regimen daily
❑ Use low procalitonin levels for prognosis
❑ Usual duration of therapy 10 days
❑ Longer in neutropenics, slow responders, undrainable foci, immunologically compromised
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Choice of antibiotics
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unknown organism
❑ Empiric therapy with broad spectrum antbiotic with good tissue penetrance
 
Neutropenic pt with severe sepsis (goal is to cover Acinetobacter & Pseudomonas spp)
❑ Use combination empirical therapy
 
Severe infections + resp failure + septic shock
❑ Extended spectrum beta lactam and aminoglycoside/fluoroquinolone
 
Streptococcus pneumoniae
beta lactam + macrolide
 
Culture specific organism
❑ Shift to appropriate anti-bacterial, antiviral or antifungal
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Remove source/foci of infection:
❑ Use minimally invasive process
❑ Source removal best done in first 12 hours
❑ Remove intravascular access devices if they are a possible source
❑ Oral chlorhexidine gluconate to reduce oral contamination as a risk factor for ventilator associated pneumonia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hemodynamic support
Fluid therapy:
❑ Administer crystalloids, use albumin when demand for fluids is too high
❑ Use dynamic variables (change in pulse pressure, stroke volume) and static variables (arterial pressure,heart rate) to assess status

Vasopressors (to achieve target MAP ≥ 65 mm Hg):
❑ Place arterial line as soon as feasible
❑ Administer norepinephrine as 1st choice drug
❑ Use epinephrine - when additional agent needed
❑ Use vasopressin 0.03 units/minute to raise MAP or decrease norepinephrine usage
❑ Selective dopamine (absolute or relative bradycardia) and phenylephrine usage


Inotropic therapy:
❑ Trial of dobutamine infusion 20 μg/Kg if cardiac output low with elevated cardiac filling pressure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corticosteroids:
❑ Use continuous flow IV hydrocortisone 200 mg/day if shock doesn’t improve with fluids & vasopressor
❑ Taper when vasopressors no longer required
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood products:
❑ Transfuse blood when hemoglobin < 7.0 g/dL
❑ Transfuse platelets if < 10,000/mm3 or < 20,000/mm3 in those with high risk
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mechanical ventilation for sepsis induced ARDS':
❑ Target tidal volume of 6 mL/Kg
❑ Target plateau pressure ≤ 30 mm Hg
❑ Use PEEP (positive end expiratory pressure) to avoid alveolar collapse
❑ Raise patients bed to 30-45°
❑ Attempt weaning when all foll. criteria are met:
  1. ❑ Pt arousable
  2. ❑ Hemodynamics stable
  3. ❑ No new complications
  4. ❑ Low ventilatory/fiO2 requirements
❑ Extubate when weaning successful
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other supportive therapy
Sedation & neuromuscular blockade:
❑ Use minimal sedation/neuromuscular blockade in mechanically ventilated patients

Glucose control:
❑ Blood glucose target value should be ≤ 180 mg/dL
❑ Use insulin infusion and 1-2 hourly monitoring to achieve target


Renal replaement therapy:
❑ May be used for management of fluid balance in hemodynamically unstable patients
❑ Use for septic patients with acute renal failure


DVT prophylaxis:
❑ Do pharmacoprophylaxis with low molecular weight heparin (LMWH), if no contraindications present
❑ Use pneumatic compression devices whenever possible


Stress ulcer prophylaxis
❑ Consider prophylaxis if risk factors are present


Feeding:
❑ Enteral & oral feeding preferred over total parenteral feeding (TPN)
❑ Adjust calorie requirement in subsequent days, as tolerated


Goals of care:
❑ Discuss goals or care, patient aspirations and future directives with family with 72 hours of admission
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Do's

  • Patients who are suspected of being severely infected, should be routinely screened for sepsis.
  • Administer antimicrobial therapy within 1 hour of diagnosis of sepsis.
  • Delay intervention, if source/foci of infection is peri-pancreatic necrosis.

Dont's

  • Antimicrobial Therapy:
    • Do not use empiric combination therapy for more than 3-5 days.
    • Do not use antimicrobial agents in severely inflamed patients, from a non-infectious cause.
  • Fluid therapy:
    • Do not use hydroxyethyl starch for resuscitation of severe sepsis and septic shock.
  • Vasopressors:
    • Do not use low dose vasopressin/dopamine/phenylephrine as monotherapy.
    • Do not use low dose dopamine for renal protection.
  • Corticosteroids:
    • Do not use corticosteroids in absence of shock.
  • Blood products:
    • Do not use erythropoietin as a specific treatment of anemia associated with sepsis.
    • Do not use antithrombin.
    • Do not use fresh frozen plasma to correct clotting abnormalities in the absence of bleeding or planned invasive procedure.
  • Other supportive therapy:
    • Do not use following therapies as their role is not clear:
IV immunoglobulins
IV selenium
    • Do not use pulmonary artery catheters routinely.
    • Do not use bicarbonate therapy as prophylaxis of hypoperfusion induced lactic acidosis if pH > 7.15.